This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-11. Anything still debated is marked as such rather than presented as settled.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
Peptide handling begins with careful receipt and inventory. Containers should be inspected for damage, label information should match the certificate of analysis, and storage location should be recorded. Many lyophilized peptides are electrostatic and may cling to vial walls or weighing paper, which can complicate transfer. Allowing a cold vial to equilibrate to room temperature before opening reduces condensation on the contents. Clean tools, gloves, and a low-humidity workspace limit contamination and moisture exposure during manipulation.
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (lyophilized) | -20°C | Stable for months to years; avoid frost-free freezers |
| Storage temperature (solution) | -80°C | Single-use aliquots preferred; avoid repeated freeze-thaw |
| Reconstitution solvent | Sterile water or buffer | Choice depends on peptide solubility and application |
| Container material | Glass or polypropylene | Low protein-binding surfaces reduce adsorption |
| Shipping condition | Dry ice | Insulated packaging maintains cold chain during transit |
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
== External links == Clinical trial number NCT03669588 for "An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT)" at ClinicalTrials.gov
clinafloxacin gatifloxacin moxifloxacin sitafloxacin prulifloxacin besifloxacin delafloxacin Two structurally related fourth-generation drugs, but formally not 4-quinolones, are gemifloxacin and trovafloxacin (removed from clinical use). In development:
=== Background === The name CosMc originated as a McDonaldland character, appearing in McDonald's advertisements from 1986 to 1992. CosMc is an extraterrestrial who "craves McDonald's food." The character occasionally came to steal food for his planet, CosMcland. It also spoke in a mixture of robot-esque sounds and normal speech. In 2023, McDonald's started focusing more on its classic mascots and the Grimace Birthday Meal became a viral Internet phenomenon. The specialty coffee-selling business had been growing, which McDonald's CEO Chris Kempczinski described as an "attractive and fast growing category". CNN described CosMc's as McDonald's "answer to Starbucks."
A reliable means of propulsion for the submerged vessel was only made possible in the 1880s with the advent of the necessary electric battery technology. The first electrically powered boats were built by Isaac Peral y Caballero in Spain (who built Peral), Dupuy de Lôme (who built Gymnote) and Gustave Zédé (who built Sirène) in France, and James Franklin Waddington (who built Porpoise) in England. Peral's design featured torpedoes and other systems that later became standard in submarines.
In addition to reworking Xen from scratch, as the team members got closer to release, they recognized they saw the game more as an entry for new players into the Half-Life series, and worked to introduce designs and features that would be more appropriate a decade since Half-Life's release. They made combat more interesting by improving the enemy's artificial intelligence while creating combat areas with more cover and options for the player. Because of their expansion of Xen, they also wanted to make sure players were not slowed down in the earlier parts of the game, and made redesigns in some of these levels. The release of Xen in the early access version of Black Mesa had been pushed off a few times; initially planned for a December 2017 release, a beta version of a segment of the remade Xen was released in June 2019 for stress-testing by players The full beta was released on December 6, 2019. Additional Xen levels were added over time, and by December 24, 2019, the full Xen chapter was released as part of the game's early access. The finished Black Mesa was released for Windows on March 6, 2020. By chance, this release was about two weeks before Valve's official return to the Half-Life universe after 13 years with the virtual reality game Half-Life: Alyx. Black Mesa project lead Adam Engels said this was not intentional as they had planned to have Black Mesa out earlier, but the attention to Alyx had helped to boost interest in Black Mesa.
Sources: en.wikipedia.org
The activated receptor must first interact with other proteins inside the cell before the ultimate physiological effect of the ligand on the cell's behavior is produced. Often, the behavior of a chain of several interacting cell proteins is altered following receptor activation. The entire set of cell changes induced by receptor activation is called a signal transduction mechanism or pathway.
In the war against the Marcomanni in 167, the town was hard pressed; its fortifications had fallen into disrepair during the long peace. Nevertheless, when in 168 Marcus Aurelius made Aquileia the principal fortress of the empire against the barbarians of the North and East, it rose to the pinnacle of its greatness and soon had a population of 100,000. Septimius Severus visited in 193. In 238, when the town took the side of the Senate against the emperor Maximinus Thrax, the fortifications were hastily restored, and proved of sufficient strength to resist for several months, until Maximinus himself was assassinated.
The directly elected leaders of territorial authorities are called mayors. They chair local council meetings and have limited executive powers, including the ability to appoint a deputy mayor, establish committees, and select chairpersons for said committees. Their constitutional role, as laid out in the Local Government Act 2002, is to provide leadership to their councillors and citizens of their districts, and to guide the direction of council plans and policies.
=== Expression === C3orf62 is expressed in more than 30 different tissues; highest expression is in whole blood. Specifically, highest expression of C3orf62 is in the following tissues: lung, tonsil, trachea, small intestine, mammary gland, and salivary gland. Through analysis of various microarray studies, C3orf62 is found to have consistently high expression compared to other genes tested in the datasets. C3orf62 has low expression in brain tissues.
Founded in 1984, Bio-Synthesis, Inc. was known as OCS Laboratories and was one of the first companies providing commercially available synthetic oligonucleotides to the biomedical research community worldwide. It was the first producer of commercially available synthetic DNA and became a producer of synthetic peptides in 1985, and became the only company to provide both synthetic DNA and peptide under one roof. Also in 1985 the process, now known as PCR, was discovered by Mullis et al. A key activity for Bio-Synthesis was to synthesize large number of PCR primer thus assisting and solidifying the early adoption of this now common and crucial process in biology.
Sources: en.wikipedia.org
Common solvents include sterile water, phosphate-buffered saline, and water-acetonitrile mixtures. The choice depends on the peptide's solubility profile and the buffer compatibility for the intended application. Manufacturers often provide a recommended solvent on the product information sheet.
Solutions are typically stored at -80°C in single-use aliquots to avoid repeated freeze-thaw cycles. They should be protected from light and kept in low-binding containers. Some peptides require a carrier protein or cryoprotectant to prevent adsorption and aggregation.
Records should include the lot number, date received, storage temperature, and any handling steps. A log of freeze-thaw cycles and aliquot preparation helps track stability. This documentation supports traceability and quality control.
It should first equilibrate to room temperature in a sealed container to prevent condensation on the cold contents. Opening too soon can introduce moisture and reduce stability, and the waiting period depends on vial size and packaging.